|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
JP5879256B2
(ja)
|
2009-05-02 |
2016-03-08 |
ジェンザイム・コーポレーション |
神経変性障害のための遺伝子治療
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
US9272053B2
(en)
|
2010-04-23 |
2016-03-01 |
University Of Massachusetts |
AAV-based treatment of cholesterol-related disorders
|
|
EP3567106A1
(en)
|
2010-04-23 |
2019-11-13 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
US9226976B2
(en)
|
2011-04-21 |
2016-01-05 |
University Of Massachusetts |
RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
CN107012171B
(zh)
|
2011-04-22 |
2021-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
KR20160010526A
(ko)
*
|
2013-05-15 |
2016-01-27 |
리젠츠 오브 더 유니버시티 오브 미네소타 |
중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
|
|
CN105247044B
(zh)
|
2013-05-31 |
2021-05-07 |
加利福尼亚大学董事会 |
腺相关病毒变体及其使用方法
|
|
EP3564379A1
(en)
|
2013-09-13 |
2019-11-06 |
California Institute of Technology |
Selective recovery
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
EP3800191B1
(en)
|
2014-03-17 |
2025-08-20 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
|
CA3276269A1
(en)
|
2014-03-18 |
2026-03-02 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
EP3137497B2
(en)
|
2014-05-02 |
2025-03-05 |
Genzyme Corporation |
Aav vectors for retinal and cns gene therapy
|
|
US11149285B2
(en)
*
|
2014-05-14 |
2021-10-19 |
Universitat Autónoma De Barcelona |
Adenoassociated virus vectors for the treatment of lysosomal storage disorders
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
RU2020140209A
(ru)
|
2014-10-21 |
2021-01-25 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
|
US10450563B2
(en)
|
2015-02-10 |
2019-10-22 |
Genzyme Corporation |
Variant RNAi
|
|
CN116019934A
(zh)
*
|
2015-02-10 |
2023-04-28 |
建新公司 |
病毒颗粒至纹状体和皮质的增强递送
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
JP7095994B2
(ja)
|
2015-03-02 |
2022-07-05 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法
|
|
AU2016228751B2
(en)
|
2015-03-11 |
2022-01-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rp2 vectors for treating x-linked retinitis pigmentosa
|
|
ES2860712T3
(es)
|
2015-03-24 |
2021-10-05 |
Univ California |
Variantes de virus adenoasociados y métodos de uso de las mismas
|
|
WO2016164308A1
(en)
|
2015-04-06 |
2016-10-13 |
Subdomain, Llc |
De novo binding domain containing polypeptides and uses thereof
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
WO2016164642A1
(en)
|
2015-04-08 |
2016-10-13 |
The United States Of America, As Represented By The Secretary Of Health And Human Services |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
IL314171A
(en)
|
2015-09-28 |
2024-09-01 |
Univ Florida |
Methods and compositions for antibody-evading virus vectors
|
|
EP3364996B1
(en)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
EP3875593A1
(en)
*
|
2015-12-11 |
2021-09-08 |
California Institute of Technology |
Targeting peptides for directing adeno-associated viruses (aavs)
|
|
RU2742612C2
(ru)
*
|
2015-12-15 |
2021-02-09 |
Джензим Корпорейшн |
Векторы на основе аденоассоциированного вируса для лечения муколипидоза типа ii
|
|
WO2017136536A1
(en)
*
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
WO2017147477A1
(en)
*
|
2016-02-26 |
2017-08-31 |
University Of Florida Research Foundation, Inc. |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
KR20220108216A
(ko)
*
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
KR102799528B1
(ko)
*
|
2016-07-08 |
2025-04-23 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
|
|
EP3485005A1
(en)
*
|
2016-07-12 |
2019-05-22 |
The University Of Manchester |
Gene therapy
|
|
EP4700118A3
(en)
|
2016-07-29 |
2026-04-22 |
The Regents of the University of California |
Adeno-associated virus virions with varint capsid and methods of use thereof
|
|
EP3500676A4
(en)
*
|
2016-08-16 |
2020-07-01 |
The University of North Carolina at Chapel Hill |
METHODS AND COMPOSITIONS FOR TRANSFERRING TARGETED GENES
|
|
IL315358A
(en)
*
|
2016-08-18 |
2024-11-01 |
Univ California |
CRISPR-CAS genome engineering using a modular AAV delivery system
|
|
EP3500279A4
(en)
*
|
2016-08-19 |
2020-04-22 |
Calimmune, Inc. |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANINE CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS.
|
|
US11207382B2
(en)
|
2016-08-19 |
2021-12-28 |
University Of Florida Research Foundation, Incorporated |
Compositions for treating conditions using recombinant self-complementary adeno-associated virus
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
AU2017336440B2
(en)
|
2016-09-28 |
2022-06-02 |
Cohbar, Inc. |
Therapeutic MOTS-c related peptides
|
|
EP3518985A4
(en)
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
|
CA3040483A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Massachusetts |
Aav capsid designs
|
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
KR20250121159A
(ko)
|
2016-12-07 |
2025-08-11 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
인터류킨-1 수용체 길항제(IL-1RA) cDNA
|
|
WO2018145009A1
(en)
*
|
2017-02-06 |
2018-08-09 |
University Of Tennessee Research Foundation |
Dna-zyme based methods & compositions for treating huntington's disease
|
|
US11117930B2
(en)
|
2017-02-23 |
2021-09-14 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
WO2018191450A2
(en)
|
2017-04-14 |
2018-10-18 |
National Taiwan University Hospital |
Gene therapy for aadc deficiency
|
|
WO2018200419A1
(en)
*
|
2017-04-23 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Viral vectors comprising engineered aav capsids and compositions containing the same
|
|
JP2020518259A
(ja)
*
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
AU2018265414B2
(en)
*
|
2017-05-10 |
2022-01-20 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (APP)-dependence of viruses
|
|
EP3634978A1
(en)
|
2017-06-07 |
2020-04-15 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
EP3645052A4
(en)
*
|
2017-06-30 |
2021-07-28 |
Regents of the University of California |
ADENO-ASSOCIATED VIRUS VIRIONS WITH ASSOCIATED CAPSIDE VARIANTS AND METHODS OF USE
|
|
CN120989074A
(zh)
|
2017-07-31 |
2025-11-21 |
映像生物有限公司 |
眼部疾病的细胞模型及用于眼部疾病的疗法
|
|
TWI832036B
(zh)
*
|
2017-08-03 |
2024-02-11 |
美商航海家醫療公司 |
用於aav之遞送之組合物及方法
|
|
KR20200039617A
(ko)
|
2017-08-28 |
2020-04-16 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
아데노-연관 바이러스 캡시드 변이체 및 이의 사용 방법
|
|
IL273394B2
(en)
|
2017-09-22 |
2025-04-01 |
Genzyme Corp |
RNAI variant
|
|
US11739330B2
(en)
|
2017-09-22 |
2023-08-29 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
|
EP3684388A4
(en)
*
|
2017-09-22 |
2021-09-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF HUNTINGTON'S DISEASE
|
|
US12043848B2
(en)
*
|
2017-10-16 |
2024-07-23 |
Vigeneron Gmbh |
AAV vectors
|
|
KR102763312B1
(ko)
*
|
2017-10-20 |
2025-02-07 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
|
|
WO2019099440A1
(en)
|
2017-11-14 |
2019-05-23 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
MY204271A
(en)
*
|
2017-11-15 |
2024-08-20 |
Ucl Business Ltd |
Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
|
|
AU2018369975B2
(en)
*
|
2017-11-15 |
2022-05-19 |
Friedrich Miescher Institute For Biomedical Research |
Primate retinal pigment epithelium cell-specific promoter
|
|
WO2019102381A1
(en)
|
2017-11-21 |
2019-05-31 |
Casebia Therapeutics Llp |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
CN108085316B
(zh)
*
|
2017-12-25 |
2021-02-09 |
中国人民解放军第四军医大学 |
一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法
|
|
US20210017509A1
(en)
*
|
2018-03-23 |
2021-01-21 |
The Trustees Of Columbia University In The City Of New York |
Gene Editing for Autosomal Dominant Diseases
|
|
WO2019195444A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
JP7406677B2
(ja)
|
2018-04-03 |
2023-12-28 |
ギンコ バイオワークス インコーポレイテッド |
抗体を回避するウイルスベクター
|
|
WO2019195423A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
AU2019261646A1
(en)
|
2018-04-27 |
2020-11-12 |
Spacecraft Seven, Llc |
Gene therapy for CNS degeneration
|
|
EP3794126A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US12338267B2
(en)
|
2018-05-15 |
2025-06-24 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
EP3793615A2
(en)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Directed evolution of aav to improve tropism for cns
|
|
WO2019232517A1
(en)
*
|
2018-06-01 |
2019-12-05 |
University Of Florida Research Foundation, Incorporated |
Compositions and methods for treatment of dominant retinitis pigmentosa
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
CA3108526A1
(en)
|
2018-08-03 |
2020-02-06 |
Genzyme Corporation |
Variant rnai against alpha-synuclein
|
|
CN109022487A
(zh)
*
|
2018-08-15 |
2018-12-18 |
上海市第人民医院 |
一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
|
|
SG11202103102WA
(en)
|
2018-09-26 |
2021-04-29 |
California Inst Of Techn |
Adeno-associated virus compositions for targeted gene therapy
|
|
CN113383010B
(zh)
|
2018-09-28 |
2025-09-09 |
沃雅戈治疗公司 |
具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
|
|
JP2022512667A
(ja)
*
|
2018-10-10 |
2022-02-07 |
ウィスコンシン アラムニ リサーチ ファンデーション |
Ｋｉｒ７．１遺伝子療法ベクターおよびその使用方法
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP4461814A3
(en)
*
|
2018-10-12 |
2025-02-26 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
US20230061069A1
(en)
*
|
2018-11-13 |
2023-03-02 |
Jayandharan Giridhara Rao |
A process for producing a plurality of sumoylation target-site modified aav vector and product thereof
|
|
MX2021005824A
(es)
*
|
2018-11-26 |
2021-10-13 |
UNIV AUTòNOMA DE BARCELONA |
Genoterapia con factor 21 de crecimiento de fibroblastos (fgf21).
|
|
JP7558167B2
(ja)
|
2018-12-03 |
2024-09-30 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
オリゴベンズアミド類似体およびがん処置におけるそれらの使用
|
|
US20220089670A1
(en)
*
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
SG11202106855YA
(en)
*
|
2019-01-04 |
2021-07-29 |
Ultragenyx Pharmaceutical Inc |
Gene therapy constructs for treating wilson disease
|
|
MX2021008542A
(es)
|
2019-01-18 |
2021-11-12 |
Voyager Therapeutics Inc |
Métodos y sistemas para la producción de partículas de aav.
|
|
CN113347962B
(zh)
*
|
2019-01-23 |
2025-01-28 |
佛罗里达大学研究基金会有限公司 |
通过合理设计增强的新型aav病毒在视网膜中的高效转导和侧向扩散
|
|
CN113518784A
(zh)
|
2019-01-28 |
2021-10-19 |
科巴公司 |
治疗性肽
|
|
PL3850089T3
(pl)
|
2019-02-04 |
2024-05-06 |
Freeline Therapeutics Limited |
Polinukleotydy
|
|
EP3934698A1
(en)
*
|
2019-03-04 |
2022-01-12 |
Adverum Biotechnologies, Inc. |
Sequential intravitreal administration of aav gene therapy to contralateral eyes
|
|
US12491264B2
(en)
|
2019-03-04 |
2025-12-09 |
Duke University |
Compositions and methods for the diagnosis and treatment of retinopathies
|
|
EP3935076A1
(en)
*
|
2019-03-08 |
2022-01-12 |
Université Paris-Saclay |
Improved therapeutic method for rare ocular diseases by gene replacement
|
|
AR118465A1
(es)
|
2019-03-21 |
2021-10-06 |
Stridebio Inc |
Vectores de virus adenoasociados recombinantes
|
|
KR20220006527A
(ko)
*
|
2019-04-10 |
2022-01-17 |
프리베일 테라퓨틱스, 인크. |
리소좀 장애에 대한 유전자 요법
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
US12491263B2
(en)
|
2019-05-13 |
2025-12-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Polymer-based implant for retinal therapy and methods of making and using the same
|
|
CA3141020A1
(en)
*
|
2019-05-17 |
2020-11-26 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy targeting retinal cells
|
|
JP2022536338A
(ja)
*
|
2019-06-10 |
2022-08-15 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ａｒｓａ遺伝子移入のためのアデノ随伴ウイルス組成物およびその使用方法
|
|
CN114269352A
(zh)
|
2019-06-27 |
2022-04-01 |
佛罗里达大学研究基金会 |
用透明质酸增强aav介导的眼组织转导
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
KR20220081971A
(ko)
*
|
2019-07-15 |
2022-06-16 |
메이라지티엑스 유케이 Ii 리미티드 |
관절염 질환 치료용 변형된 aav 캡시드 단백질
|
|
CN110295151A
(zh)
*
|
2019-07-17 |
2019-10-01 |
博鑫仪器(天津)有限公司 |
一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
|
|
WO2021041324A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Duke University |
Compositions and methods for the treatment of pathological pain and itch
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
EP4025258A4
(en)
*
|
2019-09-03 |
2023-09-06 |
University of Cincinnati |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
|
|
CA3157333A1
(en)
*
|
2019-10-10 |
2021-04-15 |
Solid Biosciences Inc. |
Modified aav capsids and uses thereof
|
|
KR20220083708A
(ko)
|
2019-10-17 |
2022-06-20 |
스트라이드바이오 인코포레이티드 |
Aav 전달 카세트
|
|
AU2020367532A1
(en)
|
2019-10-17 |
2022-05-12 |
Ginkgo Bioworks, Inc. |
Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
|
|
CA3155154A1
(en)
*
|
2019-10-23 |
2021-04-29 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
US12617821B2
(en)
|
2019-11-08 |
2026-05-05 |
President And Fellows Of Harvard College; |
Engineered viral capsid polypeptides and uses thereof
|
|
EP4055030A4
(en)
*
|
2019-11-08 |
2024-05-22 |
President And Fellows Of Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
JP2023513004A
(ja)
|
2020-01-29 |
2023-03-30 |
ジェンザイム・コーポレーション |
眼科遺伝子療法のための改変されたアデノ随伴ウイルスカプシドタンパク質およびその使用方法
|
|
WO2021159069A2
(en)
*
|
2020-02-07 |
2021-08-12 |
The Trustees Of Columbia University In The City Of New York |
Reprogramming the metabolome to delay onset or treat neurodegeneration
|
|
CN115210248A
(zh)
*
|
2020-02-18 |
2022-10-18 |
北卡罗来纳大学查佩尔希尔分校 |
Aav衣壳-启动子相互作用和细胞选择性基因表达
|
|
US12258566B2
(en)
*
|
2020-02-28 |
2025-03-25 |
University Of Massachusetts |
Oligonucleotides for PRNP modulation
|
|
CA3174781A1
(en)
|
2020-03-11 |
2021-09-16 |
Massachusetts Eye And Ear Infirmary |
Gene therapy for nmnat1-associated retinal degeneration
|
|
AR122404A1
(es)
*
|
2020-03-31 |
2022-09-07 |
Univ Massachusetts |
Variantes de cápside y usos de las mismas
|
|
EP4135776A1
(en)
*
|
2020-04-14 |
2023-02-22 |
Genethon |
Vectors for the treatment of acid ceramidase deficiency
|
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
|
AU2021273447B2
(en)
|
2020-05-13 |
2026-03-05 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
JP2023529503A
(ja)
*
|
2020-06-13 |
2023-07-10 |
オクロジェネクス インコーポレイテッド |
網膜症のためのａａｖ媒介性遺伝子導入
|
|
CN113952472A
(zh)
*
|
2020-07-21 |
2022-01-21 |
英斯培瑞有限公司 |
用于治疗眼部疾病的组合物和方法
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
WO2022031756A1
(en)
|
2020-08-05 |
2022-02-10 |
Spacecraft Seven, Llc |
Csrp3 (cysteine and glycine rich protein 3) gene therapy
|
|
IL300263A
(en)
|
2020-08-07 |
2023-03-01 |
Spacecraft Seven Llc |
Plakophilin-2 (PKP2) gene therapy using an AAV vector
|
|
MX2023002016A
(es)
|
2020-08-19 |
2023-06-26 |
Sarepta Therapeutics Inc |
Vectores de virus adenoasociados para el tratamiento del sindrome de rett.
|
|
CA3191543A1
(en)
*
|
2020-09-04 |
2022-03-10 |
Lei Cao |
Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain
|
|
WO2022087238A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Wisconsin Alumni Research Foundation |
Anti-apoptotic vector and method of using the same
|
|
US20220160825A1
(en)
*
|
2020-11-25 |
2022-05-26 |
The Penn State Research Foundation |
Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
|
|
WO2022178410A1
(en)
*
|
2021-02-22 |
2022-08-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Viral vector-based gene therapy for ocular conditions
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
US20240218396A1
(en)
*
|
2021-04-26 |
2024-07-04 |
Grace Science, Llc |
Compositions and methods for treating ngyl1 deficiency
|
|
WO2022235566A1
(en)
*
|
2021-05-03 |
2022-11-10 |
North Carolina State University |
Compositions and methods related to the treatment of ocular diseases in equines
|
|
EP4399314A4
(en)
*
|
2021-09-06 |
2025-09-10 |
Huidagene Therapeutics Singapore Pte Ltd |
TREATMENT OF EYE DISEASES AND DISORDERS ASSOCIATED WITH RPE65
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CA3238867A1
(en)
|
2021-11-29 |
2023-06-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
CN118660913A
(zh)
|
2022-02-21 |
2024-09-17 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
EP4499154A1
(en)
*
|
2022-03-25 |
2025-02-05 |
REGENXBIO Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
JP2025516136A
(ja)
*
|
2022-04-19 |
2025-05-27 |
シャンハイ ヴァイタルゲン バイオファーマ カンパニー リミテッド |
神経変性疾患の治療のための組み換えａａｖベクター
|
|
US20250171778A1
(en)
*
|
2022-04-25 |
2025-05-29 |
Myrtelle Inc. |
Treatments of Disorders of Myelin
|
|
IL316305A
(en)
|
2022-04-25 |
2024-12-01 |
Hadasit Med Res Service |
Methods and preparations for treating vision loss
|
|
JP2025517628A
(ja)
|
2022-05-06 |
2025-06-10 |
ノバルティス アーゲー |
新規の組換えａａｖ ｖｐ２融合ポリペプチド
|
|
WO2023240220A1
(en)
*
|
2022-06-09 |
2023-12-14 |
The University Of North Carolina At Chapel Hill |
Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
US20260000790A1
(en)
|
2022-07-08 |
2026-01-01 |
Ospedale San Raffaele S.R.L. |
Transgene cassettes
|
|
WO2024015794A2
(en)
*
|
2022-07-12 |
2024-01-18 |
The Research Institute At Nationwide Children's Hospital |
Adeno-associated virus gene therapy products and methods
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024218311A1
(fr)
|
2023-04-21 |
2024-10-24 |
Pulsesight Therapeutics |
Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
|
|
GB202306952D0
(en)
*
|
2023-05-11 |
2023-06-28 |
Neurochase Innovations Ltd |
Method
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
US20250197862A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
ARTIFICIAL microRNAs TARGETING TAU
|
|
TW202547561A
(zh)
|
2024-01-25 |
2025-12-16 |
美商健臻公司 |
基於ｆｕｓ向大腦遞送病毒顆粒之方法
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
TW202546230A
(zh)
|
2024-01-26 |
2025-12-01 |
美商健臻公司 |
靶向ｓｎｃａ之人工ｍｉｃｒｏｒｎａ
|
|
CN120829932A
(zh)
*
|
2024-04-18 |
2025-10-24 |
临港国家实验室 |
治疗眼部疾病的药物组合物及方法
|